EICHORCondition: Parkinson´s Disease · Sponsor: CENTOGENE GmbH Rostock
Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the establishment of a candidate biomarker in the LRRK2-positive cohort.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Tucson Neuroscience Research | Tucson, Arizona, United States | — |
| Pharmacology Research Institute | Encino, California, United States | — |
| Neuro-Pain Medical Center | Fresno, California, United States | — |
| University of California (UC) San Diego | La Jolla, California, United States | — |
| Loma Linda University | Loma Linda, California, United States | — |
| Pharmacology Research Institute | Los Alamitos, California, United States | — |
| Pharmacology Research Institute | Newport Beach, California, United States | — |
| Parkinson's Disease and Movement Disorder Center of Baco Raton | Baco Raton, Florida, United States | — |
| Linfritz Research Institute | Coral Gables, Florida, United States | — |
| Renstar Medical Research | Ocala, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| Vero Beach Neurology & Research Institute | Vero Beach, Florida, United States | — |
+ 98 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03866603